Involvement of NADPH oxidase and protein kinase C in endothelin-1-induced superoxide production in retinal microvessels.
Redox signaling has been implicated in pathophysiological changes in the vascular system. We examined whether endothelin-1 (ET-1) increases the formation of superoxide anions in retinal microvessels. Freshly isolated retinal microvessels from rats were exposed to ET-1 (100 nM), and the intracellular superoxide formation in the retinal pericytes was assessed semi-quantitatively by time-lapse fluorometric analyses using hydroethidine. The receptor mechanisms were determined by BQ-123 and BQ-788, receptor antagonists for ET(A) and ET(B) receptors, respectively, and also by IRL-1620, a selective agonist for ET(B) receptors. In addition, the changes induced by adding apocynin (10 microM), myr-PKC (1.0 microM), allopurinol (100 microM), rotenone (10 microM), or L-NAME (100 microM) with ET-1 were evaluated. Microvessels were incubated with phorbol 12-myristate 13-acetate (PMA, 10nM), a protein kinase C (PKC) activator. Fluorometric analyses showed ethidium fluorescence-positive regions that coincided well with the location of retinal pericytes. The intracellular superoxide levels were significantly increased after addition of ET-1 (100 nM), and this elevation was suppressed by apocynin or myr-PKC. Other enzyme inhibitors including L-NAME had no effect. The ET-1-induced increase of superoxide was significantly suppressed by BQ-123 (1.0 microM), while effects of adding BQ-788 (1.0 microM) were insignificant. IRL-1620 (100 nM) did not increase superoxide formation significantly. PMA (10nM) mimicked the effect of ET-1. These results suggest that ET-1 increases the formation of superoxides in the retinal microvascular pericytes most likely by activating NADPH oxidase through ET(A) receptors. The activation of PKC may be involved in the mechanism. Thus, ET-1 may augment its vasoconstrictive effects through the formation of superoxide, which may impair the bioavailability of nitric oxide in the retinal microvasculature.
Matsuo
Junko
J
Department of Ophthalmology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan.
Oku
Hidehiro
H
Kanbara
Yuko
Y
Kobayashi
Takatoshi
T
Sugiyama
Tetsuya
T
Ikeda
Tsunehiko
T
D000818:Animals; D045222:Electron Transport Chain Complex Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D019332:Endothelin-1 / Q000378:metabolism*; D004789:Enzyme Activation; D020536:Enzyme Activators / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005470:Fluorometry; D066298:In Vitro Techniques; D008297:Male; D055806:Microvessels / Q000201:enzymology; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D010084:Oxidation-Reduction; D020286:Pericytes / Q000187:drug effects / Q000201:enzymology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D044022:Receptor, Endothelin A / Q000378:metabolism; D044023:Receptor, Endothelin B / Q000378:metabolism; D012171:Retinal Vessels / Q000187:drug effects / Q000201:enzymology*; D015398:Signal Transduction; D013481:Superoxides / Q000378:metabolism*; D013997:Time Factors; D014475:Uncoupling Agents / Q000494:pharmacology; D015854:Up-Regulation; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors / Q000378:metabolism
D045222:Electron Transport Chain Complex Proteins; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D019332:Endothelin-1; D020536:Enzyme Activators; D004791:Enzyme Inhibitors; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D014475:Uncoupling Agents; D013481:Superoxides; D019001:Nitric Oxide Synthase; D014969:Xanthine Oxidase; D019255:NADPH Oxidases; D011493:Protein Kinase C